NCAM1 and neoplasm: Beside CD8+ T cells, the contribution of CD56+ NK cells as cytotoxic effectors during early regression phase is supported by the activation of NK cell receptors in the tumor bed [23, 24] and the increased NK cell number in regressing melanocytic lesions [21].